HOME >> MEDICINE >> NEWS
FDA approves new indication for Topamax as initial monotherapy for adults and children with epilepsy

TITUSVILLE, NJ, June 30, 2005 -- The U.S. Food and Drug Administration (FDA) yesterday approved a new use for TOPAMAX (topiramate) Tablets and TOPAMAX (topiramate capsules) Sprinkle Capsules as initial monotherapy in patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.

Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than two seizures in the three months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

"Anti-epilepsy medications, or neuromodulators, are selected based on seizure type; however, the specific seizure type may not always be obvious at the time of diagnosis," said Tracy Glauser, M.D., director of the Comprehensive Epilepsy Center at the Cincinnati Childrens Hospital. "A treatment like TOPAMAX, which provides coverage for both partial-onset and primarily generalized tonic-clonic seizures, offers doctors an option in situations where differentiating between these seizure types is difficult."

Epilepsy is characterized by seizures, which are abnormal electrical discharges in the brain that temporarily disrupt normal brain function. Seizures are classified as "generalized," originating in both sides of the brain simultaneously, or "partial-onset," starting in one area of the brain.

In a double-blind clinical trial, 470 patients with partial-onset or primary generalized tonic-clonic seizures were randomized to treatment with 50 mg or 400 mg/day of TOPAMAX. The primary efficacy assessment was a group comparison of time to first seizure during the double-blind phase of the study. Comparison of the Kaplan-Meier survival curves of time to first seizure favored the 400 mg/day group over the 50mg/day group. The recommended dose for monotherapy in patients 10 years of age and older is 400 mg/da
'"/>

Contact: Debbie Harvey
dharvey@golinharris.com
312-729-4374
Golin/Harris International
30-Jun-2005


Page: 1 2 3

Related medicine news :

1. DFG approves 11 new Collaborative Research Centers
2. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
3. FDA approves Dey, L.P.s Perforomist inhalation solution for maintenance treatment of COPD
4. VCR -- FDA approves home discharge for US patients
5. FDA approves prescription Zaditor for over-the-counter relief from itchy eyes
6. FDA approves Vectibix to treat patients with metastatic colorectal cancer
7. 5,000 rare diseases need drugs, but Europe only approves a handful each year
8. FDA approves room temperature storage of ZLB Behrings Helixate FS
9. FDA approves first blood test to predict risk for stroke
10. FDA approves Boostrix a new US vaccine for adolescents against pertussis
11. Majority of herb users dont follow evidence-based indications, researchers find

Post Your Comments:
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... of the peer-reviewed journal Lipids in Health and ... value—of Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ... according to SPINS scan data, the product was ... to other omega-3 products in the marketplace. The ...
(Date:7/29/2014)... Clara, CA (PRWEB) July 29, 2014 ... Valley Boomer Venture Summit concluded with the $10,000 prize ... of Bikanta. ( http://www.bikanta.com ) , The 11th Annual ... pairs investors with entrepreneurs who can bring innovative products ... , “We are pleased to have had such excellent ...
(Date:7/29/2014)... "Acceptance, Recognition, and Control (A.R.C.) Against Depression" was written ... other men to heed the call to self-help.. , Ray ... had no job, leaving Raymond with a mortgage payment he ... assistance, the emotional disturbance was so great that they put ... get to the root of his problems. , Raynond says, ...
(Date:7/29/2014)... Oconto Falls, WI (PRWEB) July 29, 2014 ... their third development project, The Cottages at MeadowLands Memory ... the growing population of those suffering from memory loss ... W.M. Enterprises, Inc., has approved the development of Oconto ... memory care. Cara Peterson, GM of The Cottages Investment ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tucson-based company ... an employer’s benefits package, or health and wellness program, ... balance while providing an effective way for employees to ... advantage of the program, employees specify the amount of ... Account. , An employer benefits from offering a 401(play)™ ...
Breaking Medicine News(10 mins):Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 3Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 4Health News:Outski launches 401(play)™ Plan to Employers as Part of an Employee Benefit / Health and Wellness Program 2
(Date:7/28/2014)... June 28 th , 2014 – Oncolab, the ... test, is making its AACC debut (booth #4051) at this ... a serum-based in vitro immunoassay, has been run for over ... the fight against cancer recurrence. Photo - ... cancer survivors in the US alone, the race is on ...
(Date:7/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: Portugal Pharmaceuticals and Healthcare ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 FREE ... economic growth last quarter has led us to ... As forecast previously, BMI expects Portugal,s ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
Cached News: